Obstructive sleep apnea (OSA) represents a significant clinical breakthrough for GLP-1 RAs in sleep medicine, culminating in the historic FDA approval of tirzepatide (Zepbound) on December 20, 2024, as the first medication specifically indicated for moderate-to-severe OSA in adults with obesity [154]. This evidence concerns the gene GCG and obesity disorder.